EPHA2 and colorectal adenoma: Notably, several TAAs currently evaluated in clinical trials, such as EphA2 [99] and Survivin [100] for GBM and MUC1 for colorectal adenoma [101], are highly expressed in some normal tissues at the mRNA level without evidence for the induction of autoimmune responses.